The US Food and Drug Administration (FDA) closed out 2025 with 16 hematology/oncology approvals in just six weeks, marking one of the most active periods of the year. Issued between early November and mid-December, the decisions spanned hematologic malignancies and solid tumors moving new evidence into clinical practice. The approvals covered a wide range of…